Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists

Merck Sharp and Dohme LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/413,077, filed Nov 12, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 8,481,556	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Ends no later than Nov 10, 2031 · Medium confidence	Merck Sharp & Dohme LLC	In force	Ends no later than Nov 10, 2031	Ends no later than Nov 10, 2031	Medium confidence
US 9,499,545	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Term ends Nov 10, 2031 · Medium confidence	Merck Sharp & Dohme LLC	In force	Term ends Nov 10, 2031	Term ends Nov 10, 2031	Medium confidence
US 9,833,448	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Term ends Nov 10, 2031 · Medium confidence	Merck Sharp & Dohme LLC	In force	Term ends Nov 10, 2031	Term ends Nov 10, 2031	Medium confidence
US 10,272,077	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Ends no later than Nov 10, 2031 · Low confidence	Merck Sharp & Dohme LLC	In force	Ends no later than Nov 10, 2031	Ends no later than Nov 10, 2031	Low confidence
US 8,912,210	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Ends no later than Dec 23, 2033 · Medium confidence	Merck Sharp & Dohme LLC	In force	Ends no later than Dec 23, 2033	Ends no later than Dec 23, 2033	Medium confidence
US 8,754,096	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC In force Ends no later than Jun 6, 2036 · Medium confidence	Merck Sharp & Dohme LLC	In force	Ends no later than Jun 6, 2036	Ends no later than Jun 6, 2036	Medium confidence
Application 16/396,056	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme LLC Abandoned Abandoned Jul 30, 2020	Merck Sharp & Dohme LLC	Abandoned	Abandoned Jul 30, 2020	not computed
Application 16/940,943	Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists Merck Sharp & Dohme Corp. Abandoned Abandoned Apr 26, 2023	Merck Sharp & Dohme Corp.	Abandoned	Abandoned Apr 26, 2023	not computed

8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

6 of these are in force and held by Merck Sharp and Dohme LLC.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.